We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-3.33%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$182M
AUM Growth
+$21.8M
Cap. Flow
+$28.1M
Cap. Flow %
15.45%
Top 10 Hldgs %
56.02%
Holding
60
New
14
Increased
20
Reduced
9
Closed
17

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$10.6M
2
ALBO
Albireo Pharma Inc
ALBO
+$4.64M
3
ACCD
Accolade Inc
ACCD
+$4.6M
4
AMED
Amedisys
AMED
+$4.16M
5
HUM icon
Humana
HUM
+$3.82M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$6.13M
2
HAE icon
Haemonetics
HAE
+$6.04M
3
EHC icon
Encompass Health
EHC
+$4.46M
4
RCM
R1 RCM Inc. Common Stock
RCM
+$3.82M
5
ZBH icon
Zimmer Biomet
ZBH
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 90.68%
2 Industrials 2.27%
3 Financials 1.02%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$458M
$23M 12.67%
323,300
-98,700
-23% -$6.13M
ALBO
2
DELISTED
Albireo Pharma Inc
ALBO
$13.9M 7.64%
445,020
+149,940
+51% +$4.64M
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$13.2M 7.26%
250,680
+178,680
+248% +$10.6M
CUE icon
4
Cue Biopharma
CUE
$135M
$9.55M 5.25%
21,840
+828
+4% +$289K
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
$9.13M 5.03%
153,400
+16,400
+12% +$969K
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
$7.46M 4.1%
490,882
+185,094
+61% +$2.89M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$2.23B
$6.78M 3.73%
274,761
+135,875
+98% +$3.2M
ALDX icon
8
Aldeyra Therapeutics
ALDX
$91.7M
$6.45M 3.55%
735,000
+139,761
+23% +$1.28M
CNVY
9
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
$6.2M 3.41%
738,012
+327,600
+80% +$2.92M
XCUR icon
10
Exicure
XCUR
$11.2M
$6.15M 3.38%
34,167
+10,167
+42% +$2.06M
KZR
11
DELISTED
Kezar Life Sciences
KZR
$5.44M 2.99%
62,996
-39,374
-38% -$2.61M
LKFT
12
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$5.26M 2.89%
+100,000
New +$5.94M
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$4.49M 2.47%
257,391
+76,220
+42% +$1.54M
ACCD
14
DELISTED
Accolade Inc
ACCD
$4.13M 2.27%
+97,988
New +$4.6M
MORF
15
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$3.96M 2.18%
70,000
+5,708
+9% +$345K
MTCR
16
DELISTED
Metacrine, Inc. Common Stock
MTCR
$3.93M 2.16%
1,145,034
+275,952
+32% +$861K
MGTX icon
17
MeiraGTx Holdings
MGTX
$1.09B
$3.84M 2.11%
291,080
+17,557
+6% +$240K
HUM icon
18
Humana
HUM
$46.7B
$3.5M 1.93%
+9,000
New +$3.82M
STTK icon
19
Shattuck Labs
STTK
$710M
$3.45M 1.9%
+169,241
New +$3.62M
OSCR icon
20
Oscar Health
OSCR
$8.5B
$3.28M 1.8%
188,400
+133,400
+243% +$2.26M
PGNY icon
21
PUT
Progyny
PGNY
$2.44B
$3.08M 1.69%
+55,000
New +$3.04M
AMED
22
DELISTED
Amedisys
AMED
$2.98M 1.64%
+20,000
New +$4.16M
AGL icon
23
Agilon Health
AGL
$1.64B
$2.87M 1.58%
+4,380
New +$3.74M
VRTX icon
24
Vertex Pharmaceuticals
VRTX
$121B
$2.72M 1.5%
15,000
-12,100
-45% -$2.36M
HAE icon
25
Haemonetics
HAE
$3.58B
$2.71M 1.49%
38,319
-95,681
-71% -$6.04M
1
2 3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q3 2021 Portfolio in Review

As of Q3 2021, Prosight Management held 60 positions worth $182M, up 14% from $160M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Prosight Management deployed $28.1M of net new capital in Q3 2021, opening 14 new positions and adding to 20 existing holdings. Its largest new stake was Accolade Inc: 97,988 shares worth $4.13M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Prothena Corp, an estimated $6.13M trimmed.

  • Prosight Management's largest Q3 2021 buy was Accolade Inc: 97,988 shares worth $4.13M.
  • Prosight Management added most to Lakefront Biotherapeutics American Depositary Shares in Q3 2021, an estimated $10.6M increase.
  • Prosight Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $6.13M.
  • Prosight Management fully exited R1 RCM Inc. Common Stock in Q3 2021, selling an estimated $3.82M.
  • Prosight Management's ten largest holdings make up 56% of its $182M portfolio in Q3 2021.
  • Prosight Management opened 14 new positions and closed 17 in Q3 2021.
  • Prosight Management's portfolio value rose 14% quarter-over-quarter to $182M.

Based on Prosight Management's 13F filing for Q3 2021, filed 12 Nov 2021.